Giles Richard Platford Sells 31,083 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Richard Platford sold 31,083 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30. Following the transaction, the insider owned 315,838 shares in the company, valued at approximately $5,400,829.80. This trade represents a 8.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $17.41 on Friday. The firm’s fifty day simple moving average is $16.53 and its 200-day simple moving average is $17.14. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The stock has a market capitalization of $55.77 billion, a price-to-earnings ratio of 51.19 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $6.90 billion during the quarter. As a group, equities analysts forecast that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Takeda Pharmaceutical in the 4th quarter valued at approximately $998,000. Quantinno Capital Management LP increased its position in Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after purchasing an additional 219,999 shares during the period. Bleakley Financial Group LLC increased its position in Takeda Pharmaceutical by 19.0% during the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after purchasing an additional 68,844 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth approximately $351,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

More Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.